Gene therapy boosts brain tumor fight in new trial
NCT ID NCT03603405
First seen Apr 06, 2026 · Last updated Jun 23, 2026 · Updated 14 times
Summary
This study tests a gene therapy (HSV-tk) plus valacyclovir alongside radiation and chemotherapy for people newly diagnosed with glioblastoma or anaplastic astrocytoma. The goal is to see if this combination improves survival. About 62 participants will receive the gene therapy injected into the tumor site, followed by standard treatments. The trial is currently recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOBLASTOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Houston Methodist Neurological Institute
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
gene therapy (HSV-tk) plus valacyclovir
What this could lead to
If successful, this could offer a new way to extend survival for people with aggressive brain tumors by making standard treatments more effective.
What could go wrong
This is an early-phase trial with only 62 participants, so results may not apply to everyone. Gene therapy carries risks like inflammation or infection, and the added benefit over standard care is not yet proven.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.